168 related articles for article (PubMed ID: 19260121)
1. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Verma D; Fava C; Kantarjian H; Cortes J
Am J Hematol; 2009 Apr; 84(4):256-7. PubMed ID: 19260121
[No Abstract] [Full Text] [Related]
2. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
3. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
4. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
5. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
[TBL] [Abstract][Full Text] [Related]
7. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Inokuchi K; Yamaguchi H; Tamai H; Dan K
J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
[No Abstract] [Full Text] [Related]
8. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
9. Circumventing resistance to kinase-inhibitor therapy.
Druker BJ
N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
[No Abstract] [Full Text] [Related]
10. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Jabbour E; Kantarjian H; Cortes J
Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
[TBL] [Abstract][Full Text] [Related]
11. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
12. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
13. [Molecular targeting therapy for chronic myeloid leukemia].
Kimura S
Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
[No Abstract] [Full Text] [Related]
14. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Swords R; Alvarado Y; Cortes J; Giles FJ
Curr Hematol Malig Rep; 2007 May; 2(2):83-8. PubMed ID: 20425355
[TBL] [Abstract][Full Text] [Related]
15. [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Liu H; Chen XG
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):561-3. PubMed ID: 17236546
[No Abstract] [Full Text] [Related]
16. Kinase inhibitors in chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
18. Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Aoki J; Ohashi K; Kobayashi T; Kakihana K; Hirashima Y; Sakamaki H
Leuk Lymphoma; 2012 Jul; 53(7):1412-4. PubMed ID: 22168276
[No Abstract] [Full Text] [Related]
19. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
[TBL] [Abstract][Full Text] [Related]
20. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]